Dermatomyositis: When Muscle Inflammation Meets Skin Rash
Dermatomyositis is a chronic autoimmune inflammatory disease characterized by muscle inflammation causing weakness and a distinctive skin rash. The disease affects both muscle and skin, distinguishing it from other myopathies. The muscle inflammation is called myositis. Myositis causes inflammation of skeletal muscles throughout the body. The characteristic skin rash gives dermatomyositis its name. The rash typically precedes or accompanies muscle symptoms. Dermatomyositis affects approximately five to ten people per one million worldwide. The disease can develop at any age but has a bimodal age distribution. One peak occurs in children aged five to fourteen years. Another peak occurs in adults aged forty to sixty years. Adults with dermatomyositis have higher cancer risk than the general population. Approximately twenty to thirty percent of adult dermatomyositis patients have underlying malignancy. The cancer risk necessitates cancer screening. Children with dermatomyositis rarely have associated malignancy. Women are affected slightly more frequently than men. Dermatomyositis is caused by abnormal immune activation targeting muscle and skin. Autoimmune antibodies attack muscle tissue. Antibodies against myositis-specific antigens develop. Anti-Jo-1 antibodies are present in about thirty percent. Anti-Mi-2 antibodies are present in about twenty percent. Other myositis-specific antibodies occur in various patients. T cells infiltrate muscle tissue. The inflammatory process damages muscle cells. Muscle fiber necrosis occurs. The muscle becomes weak and painful. Skin involvement results from immune attack on skin tissue. Antibodies against skin components develop. T cells infiltrate skin. The characteristic rash develops. The distinctive appearance of the rash helps with diagnosis. Early diagnosis and appropriate treatment are crucial for preventing permanent muscle weakness and disability. With modern treatments, remission or good disease control is achievable in most patients. Understanding Dermatomyositis helps with early recognition and appropriate management to prevent severe disability.
How Does Immune Attack on Muscles and Skin Cause Dermatomyositis?
To understand Dermatomyositis, we need to learn about muscles, skin, and the immune system. Skeletal muscles are the large muscle groups throughout the body. Muscles work by contraction and relaxation. Muscles are controlled by motor neurons. The motor neuron and muscle fiber form the neuromuscular junction. In Dermatomyositis, the immune system attacks muscle tissue. B cells produce autoimmune antibodies against muscle components. Myositis-specific antibodies target intracellular antigens. These antibodies are highly specific for dermatomyositis. T cells infiltrate muscle tissue. CD8 positive T cells attack muscle fibers directly. CD4 positive T cells help coordinate immune response. The inflammatory cells produce inflammatory cytokines. Interleukin-1, interleukin-6, and TNF-alpha are elevated. These cytokines activate more immune cells. The inflammation spreads throughout muscles. Muscle fiber necrosis occurs. Muscle fibers are damaged and destroyed. The damaged muscle fibers are removed by immune cells. Regeneration of muscle fibers occurs but is incomplete. Progressive muscle damage and loss of muscle fibers leads to muscle weakness. The characteristic muscle involvement in dermatomyositis. Proximal muscle weakness. Hip muscles affected. Thigh muscles affected. Shoulder muscles affected. Upper arm muscles affected. Muscles close to the trunk are predominantly affected. Distal muscles in hands and feet usually spared. This proximal predominance is characteristic of myositis. The weakness is symmetric, affecting both sides equally. In dermatomyositis, skin involvement is distinctive. The skin undergoes immune attack. Antibodies against skin dermal-epidermal junction. T cell infiltration of dermis. The inflammatory process damages skin. The characteristic rash develops. The rash appears in characteristic locations. Facial rash affecting cheeks and bridge of nose. Periorbital edema around eyes. Heliotrope rash, purple discoloration of eyelids. The heliotrope appearance is highly distinctive. The facial rash may extend to neck and chest. Gottron’s papules on the knuckles. Erythematous papules over the joints of the hands. The papules are characteristic and help distinguish dermatomyositis from other conditions. Photosensitive rash on sun-exposed areas. Chest and back rashes. The rashes are often itchy or painful. The inflammatory process causes progressive damage to skin. Unlike some other autoimmune skin diseases, the rash in dermatomyositis may cause permanent skin changes. Skin atrophy and thinning. Hyperpigmentation and hypopigmentation. Ulceration in severe disease. The systemic inflammation affects other organs. Lung involvement causing interstitial lung disease. Cardiac involvement causing myocarditis. Gastrointestinal involvement causing dysphagia. The multi-organ involvement makes dermatomyositis a serious systemic disease. Understanding the inflammatory mechanisms has led to development of targeted treatments.
What Are the Main Symptoms and Signs of Dermatomyositis?
Dermatomyositis causes variable symptoms affecting muscles, skin, and potentially other organ systems. The symptoms develop gradually in most cases. Muscle weakness is the primary symptom. Proximal muscle weakness affecting shoulders and hips. Difficulty raising arms overhead. Difficulty combing hair or washing hair. Difficulty rising from sitting position. Difficulty climbing stairs. Difficulty getting up from the floor. The weakness progresses gradually. Early weakness is mild and barely noticeable. Progressive weakness develops over weeks to months. Severe weakness can develop causing severe disability. The proximal distribution of weakness is characteristic. Distal muscles in hands and feet usually spared initially. However, as disease progresses, distal weakness can develop. Muscle pain may occur. Myalgia, or muscle pain. Pain with muscle use. Soreness of muscles. The muscle pain varies in severity. Some have severe pain. Others have minimal pain. Muscle swelling may occur. Muscles may appear swollen and edematous. Swelling accompanies inflammation. Swelling may cause pain and tightness. The heliotrope rash is highly distinctive. Purple or violaceous discoloration of eyelids. Swelling of eyelids. The appearance resembles heliotrope flower. The rash is present on upper eyelids. The heliotrope rash is pathognomonic for dermatomyositis. Presence of heliotrope rash strongly suggests diagnosis. Periorbital edema and erythema. Swelling around eyes. Redness of skin around eyes. The periorbital area appears inflamed. Gottron’s papules on knuckles. Erythematous papules over joints. Typically over knuckles of hands. May extend to PIP and DIP joints. The papules are painful or itchy. Gottron’s papules are highly characteristic. Flat erythematous lesions similar to Gottron’s papules. Occur on dorsal hands without papular appearance. Face rash with malar distribution. Rash of cheeks and bridge of nose. May resemble lupus malar rash. However, heliotrope rash and Gottron’s papules distinguish dermatomyositis. Neck and chest rash. V-neck distribution on chest. Extension to neck. Shoulders and upper back may be affected. Photosensitive rash on sun-exposed areas. Worse with sun exposure. Improves with sun avoidance and protection. Itching and pain of rash. The rash may be itchy. The rash may be painful. Burning sensation. The rash worsens with sun exposure. Fatigue is very common. Profound exhaustion. Systemic inflammation causes fatigue. Fatigue is often profound and disabling. Fatigue may exceed fatigue from muscle weakness. Fever may occur. Low-grade fever. Fever accompanying active disease. Fever indicates active inflammation. Weight loss may develop. Loss of appetite from systemic inflammation. Reduced food intake. Weight loss results. Rapid weight loss may prompt medical evaluation. Dysphagia, or difficulty swallowing. Weakness of pharyngeal muscles. Difficulty swallowing solid food. Difficulty swallowing liquids. Risk of aspiration. Aspiration pneumonia risk. Dysphonia, or voice changes. Weakness of vocal cord muscles. Hoarse voice. Weak voice volume. Difficulty projecting voice. Shortness of breath may occur. Lung involvement causing interstitial lung disease. Progressive shortness of breath. Dyspnea on exertion. Dry cough. Progressive respiratory impairment. Chest pain may occur. Myocarditis from cardiac involvement. Chest pain with exertion. Palpitations. Arrhythmias. Heart failure risk. Joint pain and swelling may occur. Arthralgia. Non-erosive arthritis. Joints usually not permanently damaged. Systemic symptoms. Malaise and feeling of illness. Fever and chills during flares. Depression and mood changes. The chronic disease affects mental health. Anxiety about progressive weakness. Understanding the symptoms helps prompt diagnosis and treatment.
How is Dermatomyositis Detected and Diagnosed?
Dermatomyositis is diagnosed through a combination of clinical findings, laboratory tests, imaging, and muscle biopsy. Early diagnosis is important for preventing permanent muscle damage. Clinical history of progressive muscle weakness is important. Gradual onset over weeks to months. Proximal muscle weakness. Difficulty with overhead activities. Difficulty with stair climbing. History of skin rash. Characteristic rash appearance. Facial rash. Heliotrope rash. Gottron’s papules. Photosensitive rash. The combination of muscle weakness and characteristic rash strongly suggests dermatomyositis. Physical examination reveals characteristic findings. Proximal muscle weakness. Muscle strength testing shows weakness of hip flexors, knee extensors, shoulder abductors, and shoulder flexors. Distal muscles usually preserved. Characteristic skin findings. Heliotrope rash on eyelids. Gottron’s papules on knuckles. Face rash. Neck and chest rash. Photosensitive rash areas. Skin examination supports diagnosis. Muscle tenderness on palpation. Muscles may be tender to touch. Swelling of muscles. Lymph node enlargement. Hepatosplenomegaly in some. Creatine kinase, or CK, is markedly elevated. CK level correlates with muscle damage. Normal CK is less than two hundred units per liter. Dermatomyositis usually causes CK elevation greater than one thousand. Often greater than five thousand. Severe disease can cause CK greater than ten thousand. CK elevation indicates active myositis. CK decreases as inflammation improves with treatment. Aldolase is elevated. Myoglobin is elevated. These enzymes are released from damaged muscle. LDH is elevated. AST and ALT may be elevated. These liver enzymes may be elevated if muscle damage severe. Autoimmune antibodies are diagnostic. Anti-Jo-1 antibodies present in about thirty percent. Anti-Mi-2 antibodies present in about twenty percent. Other myositis-specific antibodies. Anti-PL-12. Anti-EJ. Anti-OJ. These antibodies are highly specific for dermatomyositis. Presence of myositis-specific antibodies confirms diagnosis. Myositis-associated antibodies. Anti-Ro-52. Anti-U3RNP. These are less specific but support diagnosis. Rheumatoid Factor and anti-CCP antibodies. Usually negative. Negative RF and anti-CCP help exclude rheumatoid arthritis. ANA may be positive in some. Electromyography, or EMG, shows myopathic changes. Short duration, low amplitude motor units. Fibrillations and positive sharp waves. Bizarre high-frequency discharges. These EMG findings indicate myopathy. The pattern is consistent with inflammatory myositis. EMG helps confirm myositis diagnosis. MRI of muscles shows inflammation. T2 weighted imaging shows areas of increased signal. Areas of muscle inflammation. Edema in affected muscles. Fat infiltration indicating previous damage. MRI helps assess muscle involvement and guide biopsy location. Muscle biopsy is the gold standard for diagnosis. Biopsy shows characteristic changes. Inflammatory infiltrates in muscle. CD8 positive T cells. Endomysial infiltration around muscle fibers. Muscle fiber necrosis. Regenerating muscle fibers. Perifascicular atrophy. Perifascicular region of muscle shows atrophy. This finding is characteristic of dermatomyositis. Biopsy confirms diagnosis of myositis. Skin biopsy may be performed. Shows dermal inflammation. Interface dermatitis. Liquefactive degeneration of basal layer. Perivascular inflammation. Skin biopsy supports diagnosis. Chest imaging if respiratory symptoms. Chest X-ray may show interstitial infiltrates. HRCT shows interstitial lung disease. Pulmonary function testing. FVC and DLCO reduced. Monitoring for lung disease. Cardiac evaluation if cardiac symptoms. EKG shows arrhythmias if present. Echocardiography assesses cardiac function. Troponin elevation if myocarditis. Cancer screening in adults. Malignancy screening important. CT imaging. Endoscopy. Colonoscopy. Age-appropriate cancer screening. Higher cancer risk in adult dermatomyositis. The combination of clinical presentation, markedly elevated muscle enzymes, myositis-specific antibodies, myopathic EMG, inflammatory changes on muscle imaging, and characteristic muscle biopsy findings confirms diagnosis. Early diagnosis allows prompt treatment.
What Health Complications Do People with Dermatomyositis Face?
People with Dermatomyositis face serious complications from progressive muscle inflammation and systemic disease. The complications depend on disease severity and organ involvement. Progressive muscle weakness and disability. Severe proximal muscle weakness. Loss of function. Inability to perform self-care activities. Difficulty dressing, bathing, grooming. Wheelchair dependence from severe leg weakness. Severe disability limiting independence. Early treatment prevents or minimizes disability. Muscle atrophy from chronic inflammation. Progressive loss of muscle mass. Muscle fibers replaced with fat and fibrosis. Irreversible muscle damage. The muscle damage is permanent. Contractures develop from chronic weakness. Muscles shorten and become fixed. Joints lose range of motion. Movement becomes severely limited. Contractures are painful and disabling. Aspiration from dysphagia. Difficulty swallowing increases aspiration risk. Food or liquids entering lungs. Aspiration pneumonia. Serious respiratory infection. Aspiration can be life-threatening. Esophageal involvement causes strictures. Esophageal narrowing from inflammation and scarring. Difficulty swallowing solid foods. Progressive dysphagia. Esophageal dilation. Nutrition support may become necessary. Interstitial lung disease from lung involvement. Progressive lung inflammation. Pulmonary fibrosis. Progressive scarring of lungs. Restrictive lung disease. Progressive shortness of breath. Respiratory failure in severe cases. Oxygen dependence. Pulmonary complications are serious. Myocarditis from cardiac involvement. Heart muscle inflammation. Cardiac dysfunction. Heart failure. Arrhythmias. Sudden cardiac death risk. Cardiac complications are serious. Malignancy in adult-onset dermatomyositis. Increased cancer risk. Twenty to thirty percent develop malignancy. Lung cancer. Gastric cancer. Ovarian cancer. Breast cancer. Various malignancies. Cancer screening essential. Cancer risk decreases with age of disease onset. Older age at onset has higher cancer risk. Rhabdomyolysis in severe disease. Massive muscle damage. Myoglobin release into blood. Myoglobin in urine. Acute kidney injury from myoglobinuria. Life-threatening complication. Acute kidney failure can occur. Requires emergency treatment. Overlap syndrome complications. Overlap with scleroderma causes skin fibrosis. Severe skin tightening. Limited movement. Raynaud’s phenomenon. Overlap with other autoimmune diseases causes additional complications. Comorbid disease management complex. Depression and psychological impact. Chronic progressive disease depresses mood. Chronic pain and fatigue affect mental health. Anxiety about progressive disability. Grief about functional loss. Mental health support important. Medication side effects from immunosuppressive therapy. Corticosteroid side effects. Immunosuppressive drug toxicity. Long-term medication effects. Infection risk from immunosuppression. Opportunistic infections. Serious bacterial infections. Healthcare-associated infections. Severe infections in immunosuppressed patients. Chronic fatigue. Profound exhaustion persistent. Fatigue limits activity. Fatigue often exceeds weakness impact. Quality of life severely affected. Without early aggressive treatment, complications are serious. With appropriate early treatment, many complications preventable.
What Treatments Help People with Dermatomyositis?
Treatment for Dermatomyositis focuses on suppressing inflammation, preventing muscle damage, and managing systemic complications. Early aggressive treatment is crucial. Corticosteroids are first-line therapy. High-dose corticosteroids suppress inflammation rapidly. Prednisone initial dose typically one milligram per kilogram. Average dose sixty milligrams daily. High doses suppress myositis quickly. Muscle inflammation decreases. Muscle strength improves. CK levels decrease. The rapid response to corticosteroids is characteristic. Most show improvement within weeks. Muscle enzymes normalize within weeks to months. However, corticosteroid tapering is slow. Tapering too rapidly causes flare. Tapering schedule lasts months to years. Many require long-term corticosteroid therapy. Side effects from prolonged therapy. Osteoporosis, infection, diabetes, hypertension, weight gain. These require management. Immunosuppressive agents are used. Methotrexate suppresses immune activation. Used with corticosteroids. Allows lower corticosteroid doses. Effective for many. Reduces long-term corticosteroid side effects. Methotrexate toxicity requires monitoring. Azathioprine suppresses immune function. Alternative immunosuppressive agent. Mycophenolate mofetil suppresses lymphocyte proliferation. Used for dermatomyositis resistant to other agents. Cyclophosphamide for severe disease. Very potent immunosuppression. Used for life-threatening complications. Interstitial lung disease treatment. Severe disease may require cyclophosphamide. Cyclosporine suppresses T cell function. Used for dermatomyositis. Alternative immunosuppressive agent. Biologic therapies target specific immune pathways. Rituximab targets B cells. B cell depletion. Used for dermatomyositis. Shows promise for refractory disease. TNF inhibitors block TNF-alpha. Etanercept, infliximab, adalimumab. Some benefit reported. Not universally effective. IL-6 inhibitors. Tocilizumab blocks interleukin-6. Shows promise in clinical trials. May allow corticosteroid dose reduction. IV immunoglobulin suppresses immune activation. Used for severe disease. Used for refractory disease. Intravenous IgG blocks pathogenic antibodies. Effective for rapidly progressive disease. Administered in hospital setting. Physical therapy maintains function. Stretching exercises prevent contractures. Strengthening exercises build strength. Gentle activity within tolerance. Regular physical therapy crucial. Prevents loss of range of motion. Maintains as much strength as possible. Occupational therapy helps with activities of daily living. Assistive devices. Joint protection techniques. Adaptive equipment. Skin care. Sun protection important. UV protection with sunscreen. Protective clothing. Sun avoidance during peak hours. Reduces skin symptoms. Photosensitive rash prevention. Topical corticosteroids for skin rash. Reduce skin inflammation. Topical calcineurin inhibitors. Hydroxychloroquine for skin rash. Reduces photosensitive rashes. Lung disease monitoring and treatment. Pulmonary function testing. Chest imaging. Treatment of interstitial lung disease. Immunosuppressive therapy for ILD. Oxygen therapy if needed. Cardiac monitoring if cardiac involvement. EKG monitoring. Echocardiography. Troponin monitoring. Cardiac disease management. Cancer screening in adults. Regular surveillance. Age-appropriate cancer screening. Close monitoring for malignancy. Early detection improves outcomes. Nutritional support if dysphagia. Soft diet modifications. Nutrition supplements. Tube feeding if severe dysphagia. Adequate nutrition supports healing. Therapy goals are disease remission or low disease activity. Muscle strength restoration. Skin rash resolution. Corticosteroid dose reduction to minimum effective dose. Early aggressive treatment achieves remission in most patients.
Living with Dermatomyositis
Living with Dermatomyositis requires ongoing medical management, physical therapy, activity modification, and psychological adjustment to a chronic disease that can affect multiple organ systems. For people newly diagnosed with Dermatomyositis, the diagnosis can be overwhelming. Learning about a disease causing progressive muscle weakness is frightening. However, understanding that effective treatments exist and remission is achievable offers hope. Patient education about Dermatomyositis, treatment options, and disease course helps people understand their condition. Understanding that early aggressive treatment prevents disability is important. Medication compliance is essential. Taking corticosteroids and immunosuppressive agents consistently. Following tapering schedule carefully. Compliance is crucial for disease control. Missing doses allows disease activity to increase. Regular monitoring for medication side effects. Inflammatory marker monitoring. Muscle strength testing. Imaging when indicated. Blood work monitoring. Physical therapy is crucial. Regular physical therapy sessions. Home exercise program. Daily stretching to prevent contractures. Strengthening exercises as tolerated. Regular activity maintains strength and mobility. Physical therapy must continue indefinitely. Activity management. Pacing activities to avoid overexertion. Rest periods as needed. Graded exercise. Gradually increasing activity as strength improves. Excessive activity during flares may worsen symptoms. Activity modified during flares. Increased rest during active disease. Work and school adjustments may be necessary. Muscle weakness may limit work capacity. Difficulty with overhead activities. Difficulty with stair climbing. Difficulty with repetitive motions. Some people need modified work duties. Others need flexible schedules for medical appointments and physical therapy. Some need to reduce work hours. Severe weakness may necessitate disability. Disability support available. School-age children may need educational accommodations. Physical education limitations. Frequent absences for medical appointments. Physical therapy schedule. Educational accommodations for fatigue and weakness. Counselor support. Skin care is important. Daily skin care routine. Sun protection crucial. Sunscreen SPF thirty or higher. Protective clothing. Hat and sunglasses. Avoid peak sun hours. Sunscreen reapplication every two hours. Photosensitive rash prevention. Topical medications for rash. Topical corticosteroids. Hydroxychloroquine if recommended. Gentle skin cleansing. Avoid irritant products. Moisturizing regularly. Nutrition management. Adequate protein supports muscle healing. Calories adequate for energy. Calcium and vitamin D for bone health. If dysphagia, soft diet modifications. Nutritional supplements. Tube feeding if severe dysphagia. Psychological support addresses emotional impact. Depression from chronic progressive disease. Anxiety about disability. Grief about functional loss. Counseling helps address emotional challenges. Support groups. Connecting with others with dermatomyositis. Sharing experiences. Learning coping strategies. Online communities. Dating and relationships affected. Communication about limitations. Weakness affects intimacy. Sexual dysfunction from disease or medications. Open communication important. Pregnancy possible but requires medical planning. Disease activity may change during pregnancy. Some medications safe, others not. Regular medical follow-up during pregnancy. Most can have successful pregnancies. Mental health support. Depression affects many. Anxiety about progression. Mood disturbance. Counseling helps. Antidepressants may be necessary. Support groups help. Family and social support. Family understanding of disease. Education about symptoms and limitations. Assistance with difficult tasks. Emotional support crucial. Work with healthcare team. Regular ophthalmology if eye involvement. Cardiac monitoring if cardiac symptoms. Pulmonary function testing if lung involvement. Cancer screening if adult onset. Regular rheumatology follow-up. Regular assessment of disease activity and treatment response. With appropriate early aggressive treatment suppressing inflammation, regular physical therapy maintaining function, activity modification within limitations, sun protection managing skin disease, psychological support addressing emotional impact, family and social support, and regular medical monitoring, most people with Dermatomyositis can achieve remission or good disease control and maintain reasonable quality of life despite the serious nature of this systemic inflammatory disease.
Frequently Asked Questions About Dermatomyositis
FAQ 1: Is Dermatomyositis the same as polymyositis? No, Dermatomyositis and Polymyositis are different diseases. Both cause myositis with muscle inflammation and weakness. However, Dermatomyositis has a distinctive skin rash. Polymyositis does not have skin involvement. The presence of characteristic rash distinguishes Dermatomyositis. Both are autoimmune inflammatory myopathies. Both respond to similar treatments. However, the skin findings help identify Dermatomyositis specifically. The myositis-specific antibodies may differ. Both require similar treatment approaches.
FAQ 2: Can Dermatomyositis be cured? Dermatomyositis is a chronic disease without cure. However, remission is achievable with appropriate treatment. Some achieve complete remission where disease is inactive. Others maintain low disease activity requiring ongoing therapy. Complete remission on therapy is possible. However, relapse risk if therapy stopped. Long-term therapy often necessary. With appropriate treatment, quality of life improves. Most achieve significant symptom improvement.
FAQ 3: Is Dermatomyositis associated with cancer in children? Dermatomyositis in children is rarely associated with malignancy. Cancer risk is very low in childhood Dermatomyositis. Only about three to five percent have underlying malignancy. Cancer risk is much higher in adult-onset Dermatomyositis. Twenty to thirty percent of adults have malignancy. Cancer screening is important in adults. Cancer screening not routine in children. However, any symptoms should prompt evaluation.
FAQ 4: How long does Dermatomyositis treatment take? Treatment duration varies widely. Some achieve remission within weeks to months with appropriate therapy. Others require months to years for significant improvement. Most require at least one to two years of treatment. Some require indefinite long-term therapy. Corticosteroid tapering is slow. Too-rapid tapering causes flare. Individual response varies. However, most show improvement with appropriate treatment. Early aggressive treatment improves prognosis.
FAQ 5: Are there new treatments being developed for Dermatomyositis? Yes, there is ongoing research into improved Dermatomyositis treatments. Biologic therapies showing promise. Rituximab showing benefit for B cell depletion. JAK inhibitors being studied. IL-6 inhibitors showing promise. Better understanding of immune mechanisms leading to targeted therapies. Biomarker research identifying treatment responders. Gene therapy approaches being researched. Clinical trials of new medications continue. As new treatments develop, outcomes will improve. Corticosteroid-sparing strategies in development.
References and Further Reading
For more information about Dermatomyositis, you can visit several trusted and authoritative sources providing detailed information for patients and families dealing with this autoimmune inflammatory disease. The World Health Organization at WHO.int provides comprehensive information about myositis and autoimmune muscle diseases. The Myositis Association at MyositisAssociation.org offers excellent patient education, family resources, support communities, information about treatments and research, and updates about developments in myositis care. The American College of Rheumatology at Rheumatology.org provides clinical resources and patient education about inflammatory myopathies including Dermatomyositis. The National Institute of Arthritis and Musculoskeletal and Skin Diseases at NIAMS.NIH.gov offers patient education and research information about Dermatomyositis. MedlinePlus, a service of the National Library of Medicine at MedlinePlus.gov, has detailed medical information about Dermatomyositis written in language that patients and families can easily understand without specialized medical knowledge. The five main reference links are: 1) WHO.int – Myositis and Muscle Diseases, 2) The Myositis Association, 3) American College of Rheumatology, 4) NIAMS – National Institute of Arthritis, and 5) MedlinePlus – Dermatomyositis.
Disclaimer
This article adapts publicly available information from WHO’s Dermatomyositis and inflammatory myopathy information pages. This content is for informational and educational purposes only and does not constitute medical advice. ObserverVoice.com is a news and information platform — not a healthcare provider. If you or someone you know has been diagnosed with Dermatomyositis or shows signs of this condition including progressive muscle weakness, characteristic skin rash including heliotrope rash or Gottron’s papules, muscle pain, dysphagia, or other symptoms, please consult immediately with qualified healthcare professionals, rheumatologists, and dermatomyositis specialists for proper diagnostic evaluation with muscle enzyme testing, myositis-specific antibody testing, EMG, muscle imaging, and muscle biopsy as appropriate, and for appropriate early aggressive immunosuppressive treatment planning. Early diagnosis and early aggressive treatment significantly improve outcomes and prevent progressive muscle damage and disability. Cancer screening is important in adult-onset Dermatomyositis. For more information, visit WHO.int and ObserverVoice.com.
Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
